Men in the highest quartile of serum homocysteine levels had a 2.9-fold increased adjusted risk of dying from ischemic heart disease compared to the lowest quartile (95% CI 1.8-4.7).
Case-Control (n=1,355)
Do higher serum homocysteine levels increase the risk of death from ischemic heart disease in men?
Elevated serum homocysteine levels are strongly and independently associated with an increased risk of death from ischemic heart disease, supporting a potential causal role.
Effect estimate: RR 2.9 (95% CI 1.8-4.7)
p-value: p=<.001
BACKGROUND: Results from prospective studies of serum homocysteine levels and ischemic heart disease (IHD) are inconclusive. We carried out a further prospective study to help clarify the position. METHODS: In the British United Provident Association (BUPA) prospective study of 21,520 men aged 35 to 64 years, we measured homocysteine levels in stored serum samples and analyzed data from 229 men without a history of IHD at study entry who subsequently died of IHD and 1126 age-matched control subjects (nested case-control design). RESULTS: Serum homocysteine levels were significantly higher in men who died of IHD than in men who did not (mean, 13.1 vs 11.8 micromol/L; P<.001). The risk of IHD among men in the highest quartile of serum homocysteine levels was 3.7 times (or 2.9 times after adjusting for other risk factors) the risk among men in the lowest quartile (95% confidence interval CI, 1.8-4.7). There was a continuous dose-response relationship, with risk increasing by 41% (95% CI, 20%-65%) for each 5-micromol/L increase in the serum homocysteine level. After adjustment for apolipoprotein B levels and blood pressure, this estimate was 33% (95% CI, 22%-59%). In a meta-analysis of the retrospective studies of homocysteine level and myocardial infarction, the age-adjusted association was stronger: an 84% (95% CI, 52%-123%) increase in risk for a 5-micromol/L increase in the homocysteine level, possibly because the participants were younger; the relationship between serum homocysteine level and IHD seems to be stronger in younger persons than in older persons. CONCLUSIONS: Our positive results help resolve the uncertainty that resulted from previous prospective studies. The epidemiological, genetic, and animal evidence together indicate that the association between serum homocysteine level and IHD is likely to be causal. A general increase in consumption of the vitamin folic acid (which reduces serum homocysteine levels) would, therefore, be expected to reduce mortality from IHD.
Wald et al. (Mon,) conducted a case-control in Ischemic heart disease (n=1,355). Serum homocysteine vs. Lowest quartile of serum homocysteine was evaluated on Death from ischemic heart disease (RR 2.9, 95% CI 1.8-4.7, p=<.001). Men in the highest quartile of serum homocysteine levels had a 2.9-fold increased adjusted risk of dying from ischemic heart disease compared to the lowest quartile (95% CI 1.8-4.7).